Experimental graft-vs.-host disease treatment equivalent to standard care in ... Medical Xpress The combination of two immunosuppressive compounds—tacrolimus plus sirolimus—did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from Dana-Farber ... |
